<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00370669</url>
  </required_header>
  <id_info>
    <org_study_id>8411</org_study_id>
    <nct_id>NCT00370669</nct_id>
  </id_info>
  <brief_title>Effect of Intravitreal Bevacizumab on Clinically Significant Macular Edema</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shahid Beheshti University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shahid Beheshti University of Medical Sciences</source>
  <brief_summary>
    <textblock>
      to compare the effect of intravitreal bevacizumab alone or in combination with triamcinolone
      acetonide with laser photocoagulation on clinically significant macular edema (CSME)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      we entered 150 eyes into the study that recruitment of cases finished recently.Eligible eyes
      randomly assign to one of the study arms including intravitreal bevacizumzb, intravitreal
      bevacizumzb/triamcinolone and macular photocoagulation groups. Every patient needs at least 1
      year followup. During this time BCVA, OCT, FA will be done for each patient and inaccording
      to interpretation of datas and fundus exam repeatation of injection will be done.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2005</start_date>
  <completion_date>February 2007</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single</masking>
  </study_design_info>
  <primary_outcome>
    <measure>visual acuity</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>central macular thickness</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Leakage in fluorescein angiography</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>intraocular pressure</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cataract progression</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>anterior chamber reaction</measure>
  </secondary_outcome>
  <enrollment>150</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>triamcinolone acetonide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  case with clear media IOP below 23 mm/Hg female after menopause at least for 12 months
             or had 2 contraceptive roots visual acuity between 20/50 to 20/320

        Exclusion Criteria:

          -  no PRP or N.d YAG laser in past 6 months no intraocular surgery in past 12 months

          -  CVA in past 12 months blood sugar above 250

          -  active infection in extraocular adnexa
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Masoud Soheilian</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ophthalmic Research Center of Shaheed Beheshti Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Masoud Soheilian, MD</last_name>
    <phone>+98 21 22585952</phone>
    <email>labbafi@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Masoud Soheilian</name>
      <address>
        <city>Tehran</city>
        <zip>16666</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Masoud Soheilian, MD</last_name>
      <phone>+98 21 22585952</phone>
      <email>labbafi@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>February 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 30, 2006</study_first_submitted>
  <study_first_submitted_qc>August 30, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2006</study_first_posted>
  <last_update_submitted>February 21, 2007</last_update_submitted>
  <last_update_submitted_qc>February 21, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 22, 2007</last_update_posted>
  <keyword>Bevacizumab</keyword>
  <keyword>CSME</keyword>
  <keyword>MPC</keyword>
  <keyword>Triamcinolone acetonide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

